Are calcineurin inhibitors-free regimens ready for prime time?

Slides:

Advertisements

Similar presentations

The Ob protein (leptin) and the kidney

Advertisements

Volume 78, Issue 2, Pages (July 2010)

Primary Immunodeficiencies

Volume 83, Issue 3, Pages (March 2013)

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Mechanisms of Drug-Induced Allergy

Tumor Evolution: A Problem of Histocompatibility

JAK inhibitors in dermatology: The promise of a new drug class

Cyclosporine in the Treatment of Dermatologic Disease: An Update

Membranous nephropathy: When and how to treat

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Volume 77, Issue 1, Pages 6-8 (January 2010)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Volume 84, Issue 2, Pages (August 2013)

The Other Face of Chimeric Antigen Receptors

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Volume 73, Issue 7, Pages (April 2008)

Macrophages and dendritic cells: what is the difference?

Nephrology Crosswords: Hemodialysis

Volume 86, Issue 2, Pages (August 2014)

Volume 87, Issue 2, Pages (February 2015)

Volume 73, Issue 1, Pages 5-7 (January 2008)

T-cell alloimmunity and chronic allograft dysfunction

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology—Thirty Years of Progress but Still Much to Be Done

Interaction of receptor for advanced glycation end products with advanced oxidation protein products induces podocyte injury Yasuhiko Yamamoto, Hiroshi.

Volume 84, Issue 4, Pages (October 2013)

Volume 87, Issue 1, Pages (January 2015)

Disaster nephrology: crush injury and beyond

A physician's perseverance uncovers problems in a key nephrology study

Günter Weiss, Florian Kronenberg Kidney International

Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? Lionel Rostaing, Nassim Kamar Kidney International

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 74, Issue 8, Pages (October 2008)

Volume 87, Issue 3, Pages (March 2015)

Nephrology Crossword: Peritoneal Dialysis

Methods for guideline development

Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases Jennifer W. Leiding, MD, Lisa.

Extracorporeal removal of toxins

Volume 56, Issue 4, Pages (October 1999)

Nephrology Crossword: Glomerulonephritis

Santhi Voora, Deborah B. Adey American Journal of Kidney Diseases

A man with a hole in his penis

Volume 69, Issue 1, Pages (January 2006)

A possible mechanism of renal cell death after ischemia/reperfusion

Volume 82, Issue 9, Pages (November 2012)

Volume 71, Issue 12, Pages (June 2007)

Carmine Zoccali, Francesca Mallamaci Kidney International

Organ transplantation goes to the movies

Volume 80, Issue 10, Pages (November 2011)

Volume 83, Issue 4, Pages (April 2013)

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Volume 70, Issue 3, Pages (August 2006)

Volume 74, Issue 9, Pages (November 2008)

Gene targeting: Applications in transplantation research

Therapy of Alopecia Areata: On the Cusp and in the Future

Volume 82, Issue 9, Pages (November 2012)

T cells and T-cell receptors in acute renal failure

The international realities of live donor kidney transplantation

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Volume 80, Issue 9, Pages (November 2011)

A new ‘tac’ for childhood nephrotic syndrome

Volume 74, Issue 10, Pages (November 2008)

Volume 75, Issue 8, Pages (April 2009)

IgA nephropathy: markers of progression and clues to pathogenesis

The Ebf1 knockout mouse and glomerular maturation

Presentation transcript:

Are calcineurin inhibitors-free regimens ready for prime time? Flavio Vincenti Kidney International Volume 82, Issue 10, Pages 1054-1060 (November 2012) DOI: 10.1038/ki.2012.194 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 T-cell activation requires two signals. APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor. Kidney International 2012 82, 1054-1060DOI: (10.1038/ki.2012.194) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 2 Belatacept binds with high affinity to CD86 and Cd80 and prevents T-cell activation. APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor. Kidney International 2012 82, 1054-1060DOI: (10.1038/ki.2012.194) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 The low intensity belatacept treatment regimen in the phase III studies (BENEFIT and BENEFIT-EXT). i.v., intravenous. Kidney International 2012 82, 1054-1060DOI: (10.1038/ki.2012.194) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 4 The projected mean graft half-life based on the clinical profile at 3 years for the BENEFIT and BENEFIT-EXT trials (for the approved low intensity regimen). CsA, cyclosporine; LI, less intensive regimens. Kidney International 2012 82, 1054-1060DOI: (10.1038/ki.2012.194) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 5 The mechanism of action of tofacitinib. JAK, Janus kinase; STAT, signal transducer and activator of transcription. Kidney International 2012 82, 1054-1060DOI: (10.1038/ki.2012.194) Copyright © 2012 International Society of Nephrology Terms and Conditions